Stay updated by reading our latest news

Deep learning systems have widely presented promising results in cancer diagnostics [1] and for Kaiku Health, machine learning (ML) based approaches are not anything new. Previously, Oulu University Hospital (OYS) and Kaiku Health have shown that it is possible to predict both symptom and adverse event onset and continuation in patients receiving immune checkpoint inhibitor...

Kaiku Health, the developer of digital health intervention platform in oncology, today announced it will develop digital patient monitoring and management for melanoma patients in collaboration with Novartis, a leading global medicines company. Melanoma is less common than other types of skin cancer, but it can more easily spread to other parts of the body....

In May 2020, Elekta announced that it will further develop its focus on cancer care providers and their patients through its acquisition of Kaiku Health. A key element of the acquisition was that the Kaiku platform can be integrated with Elekta’s MOSAIQ® Oncology Information System. Kaiku Health is now available in the US as a...

In the spring of 2020 the world  had to quickly adapt to the new situation of COVID-19 spreading across the globe and causing lockdowns. The situation for us at Kaiku, was no different. The development of our product naturally needed to continue just like before – or even at a faster phase, as it could...

Kaiku Health has taken its first steps to tackle the big issue related to the challenge of identifying which patients are likely to benefit from immune checkpoint inhibitor (ICI) therapies. The unfortunate fact is that not all eligible patients respond to these therapies at all, and for some of those who have a response, it...